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Insulin lipohypertrophyAbstract Background: Although almost all patients with T1DM eventually develop one or more
skin manifestations, data on cutaneous manifestations of type 1 diabetes mellitus (T1DM) are
scarce. They can be the first presenting sign, or even precede the diagnosis or develop from the
long-term effects of diabetes. Objective: To detect the prevalence and spectrum of skin manifesta-
tions in children and adolescents with T1DM attending the DEMPU clinic, Cairo University and to
investigate the effect of the disease duration on these dermatoses. Subjects and methods:Two hun-
dred twenty-five children and adolescents with T1DM were examined for dermatological problems.
Of them, 152 patients who had cutaneous manifestations with T1DM were included in this case-
control study, 152 age and sex matched non diabetic patients were included as control group. A
detailed dermatological examination was carried out by the dermatology team. Results: The overall
prevalence of dermatologic manifestations was 67.56% (152 T1DM patients; 74 males and 78
females). The mean age of the patients was 8.38 ± 3.79 years and the mean diabetes duration
was 2.80 ± 2.86 years. Cutaneous adverse effects related to insulin injections were the most com-
mon manifestation representing 28.9%, followed by cutaneous infections (bacterial, fungal and
viral infections) in 25%, allergic skin diseases in 19.1% and pruritus in 15.1% of patients with
T1DM. Conclusion: Broad spectrums of dermatoses are common (67.56%) in Egyptian patients
with T1DM. Early referral to the dermatologist helps to detect skin complications of diabetes in
these children and is essential for both prevention and management of these conditions.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Although the mechanism for many diabetes-associated skin
problems remains unknown, the pathogenesis of others is
linked to abnormal carbohydrate metabolism, other altered
metabolic pathways, atherosclerosis, microangiopathy, neuron
degeneration, and impaired host mechanisms.1 It seems that
Cutaneous manifestations in children with type 1 diabetes 45diabetes, similar to other endocrine disorders, may cause some
alterations that could be derived from impaired skin
homoeostasis.2 Cutaneous manifestations generally appear
subsequent to the development of diabetes but may be the first
presenting sign or even precede the diagnosis by many years.
The cutaneous findings can be classified into four major
groups: (1) skin diseases associated with diabetes, such as
scleroderma-like changes of the hand, necrobiosis lipoidica,
and diabetic dermopathy; (2) cutaneous infections; (3) cuta-
neous manifestations of diabetes complications such as neuro-
pathic foot ulcers; and (4) skin reactions to diabetes
treatment.3
Objective
The objective of this study was to evaluate the prevalence and
the spectrum of skin manifestations in children with type 1
diabetes mellitus (T1DM) attending the Diabetes Endocrine
& Metabolism Pediatric Unit (DEMPU) clinic, Cairo
University, and to assess its relation to disease duration,
metabolic control in children and adolescents with type 1
diabetes.
Material and methods
Study population
To assess the prevalence of the cutaneous manifestations in
children with T1DM, two hundred twenty-five children and
adolescents with T1DM attending the Diabetes Endocrine
and Metabolism Pediatric Unit (DEMPU) clinic were exam-
ined for dermatological problems between December 2010
and September 2011. Patients were included if they have
T1DM, aged less than 18 years. Children with associated other
systemic diseases that may have cutaneous manifestations were
excluded.
Only one hundred fifty-two patients were found to have
cutaneous manifestations with T1DM and were included in
this case-control study (group I). They were compared to the
control group (group II).
The control group (group II) included one hundred fifty-
two age and sex matched patients with cutaneous manifesta-
tions with no history of any systemic disease.
Procedure
 All children were subjected to full history taking including
age, sex, onset, course, and duration of the present cuta-
neous lesions, associated diseases, and history of previous
skin diseases and in children with T1DM; duration of
diabetes, type of insulin therapy.
 A detailed dermatological examination was carried out by
a dermatology team and the cutaneous findings were
recorded.
 The charts of children with T1DM were reviewed for the
previous results of HbA1c in the past year to assess the
glycemic control, and thyroid profile, lipid profile and
any other available labs to rule out any associated
condition that may be associated with cutaneous
manifestations.Statistical analysis
Data were statistically described in terms of mean ± standard
deviation (±SD), median and range for quantitative data, or
frequencies (number of cases) and percentages for qualitative
data when appropriate. Comparison of numerical variables
between the study groups was done using Student’s t test for
independent samples in comparing normally distributed data
and Mann Whitney U test for independent samples in compar-
ing non-normal data. For comparing categorical data, Chi
square (c2) test was performed. Exact test was used instead
when the expected frequency is less than 5. p values less than
0.05 was considered statistically significant. All statistical
calculations were done using computer programs SPSS (Statis-
tical Package for the Social Science; SPSS Inc., Chicago, IL,
USA) version 15 for Microsoft Windows.
Results
The prevalence of cutaneous manifestations in children and
adolescents with T1DM in the study group was 67.56%
(out of the two hundred twenty-five children with
T1DM, one hundred fifty-two patients had cutaneous
manifestations).
Group (I) included 152 children with T1DM and cutaneous
manifestations (74 males and 78 females) with a mean age of
8.38 ± 3.79 years (ranging from 1.5 to 15 years). The mean
duration of diabetes was 2.80 ± 2.86 years and the mean
HbA1c was 8.91 ± 7.96%. Group II (control group) included
152 patients; 58 males (38.2%) and 94 females (61.8%), their
mean age was 5.14 ± 2.02 years (ranging from 3 to 15 years).
There was no statistical significant difference between the
two groups as regards the age and sex (p= 0.122 and 0.091,
respectively).
Regarding the spectrum and the distribution of the skin
manifestations in group I (children with T1DM), complica-
tions of insulin therapy were the most common cutaneous
manifestation in patients with T1DM and diagnosed in 44
cases (28.9%), Fig. 1. The most common insulin complica-
tion was insulin lipohypertrophy (36/44 cases) followed by
bruises at insulin injection sites (6/44 cases), brown pigmen-
tation at insulin injection sites came in the third order (2/44
cases).
Cutaneous infections were the second common cutaneous
disease in the study group (group I) diagnosed in 38 cases
(25%); they included bacterial, fungal and viral infections
(Fig. 1). Bacterial infections were diagnosed in 19 cases
(12.5%), 6 males and 13 females. Boils, impetigo and acute
paronychia were diagnosed in 16, 2, 1 case/s, respectively.
Cutaneous fungal infections were diagnosed in 17 cases
(11.2%), 3 males and 14 females. The most common cutaneous
fungal infections were candidiasis (monilial vulvovaginitis)
(11/17) cases followed by tinea versicolor, tinea corporis and
tinea capitis in 3, 2 and 1 case/s, respectively.
The most common allergic skin disease in group (I) was
papular urticaria (12/29) cases followed by pityriasis alba,
urticarial and eczema in 11, 4, 2 cases, respectively.
There was no significant difference between children with
T1DM and the control group as regards bacterial and fungal
skin infections (p= 0.737, 0.565, respectively), (Table 1).
Figure 1 The spectrum of the cutaneous manifestations in patients with T1DM. Dermatological complications of insulin therapy
represented the highest prevalence among the study group (44 cases, 28.9%) followed by cutaneous infections which occurred in 38 cases,
(25%).
Table 1 Comparison between children with diabetes (group I)
and the control group (group II) regarding the frequency of the
common cutaneous manifestations in both groups.
Cutaneous
manifestations
Group I
(n= 152)
Group II
(n= 152)
p
value
Bacterial infections 19 (12.5%) 22 (14.5%) 0.737
Cutaneous fungal
infections
17 (11.2%) 13 (8.5%) 0.565
Viral infections 2 (1.3%) 11 (7.2%) 0.023*
Allergic skin diseases 29 (19.1%) 44 (28.9%) 0.060
Pruritus 23 (15.1%) 2 (1.3%) 0.000*
Parasitic infestations 2 (1.3%) 17 (11.2%) 0.001*
Hair disorders 3 (2%) 13 (8.5%) 0.020*
Pigmentary disorders
and nevi
4 (2.6%) 1 (0.7%) 0.034*
Hyperkeratosis of soles 4 (2.6%) 1 (0.7%) 0.036*
* Significant.
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sole were significantly higher in children with T1DM
(p= 0.000, 0.034, 0.036, respectively), (Table 1).
Viral infections, parasitic infestations, and hair disorders
were significantly lower in children with T1DM (p= 0.023,
0.001, 0.020, respectively), (Table 1).
As regards sex differences in each cutaneous manifestation
in group (I) there was no significant sex difference in children
with complications of insulin therapy and pruritus (p= 0.111,
0.822, respectively) while, cutaneous bacterial and fungal infec-
tions were significantly higher in females compared to males
(p= 0.043, 0.009, respectively). However, allergic diseases
were more common in males (p= 0.022). Acne and Hyper-
hidrosis of hands were observed only in male patients (Fig. 2).
The mean age, diabetes duration, and HbA1c for children
with T1DM with different skin manifestations are summarizedin Table 2. The mean age for patients with complications
of insulin therapy was 9.49 ± 3.38, mean duration was
3 ± 1.59, and HbA1c was 7.73 ± 1.41.
Children with complications of insulin treatment had signif-
icantly older age and longer diabetes duration compared to
other children with T1DM (p= 0.02 and 0.004, respectively)
while, there was no significant difference regarding the sex or
the mean HbA1c (p= 0.111, 0.102, respectively).
Cutaneous bacterial and fungal infections were significantly
higher in females compared to males (p= 0.043, 0.009, respec-
tively). Patients with T1DM and bacterial infections had sig-
nificantly younger age compared to other patients with
T1DM (p= 0.015) while there was no significant difference
as regards diabetes duration or HbA1c (p= 0.015 and 0.617,
respectively). There was no significant difference between
patients with T1DM and fungal infections and other children
with T1DM as regards age, diabetes duration and HbA1c
(p= 0.091, 0.439 and 0.701, respectively).
Allergic skin diseases were significantly higher in males than
females (20 cases, 68.9% versus 9 cases, 31.1%, p= 0.022).
Patients with T1DM and allergic skin diseases had significantly
shorter diabetes duration (p= 0.047) but no significant differ-
ence as regards the age and HbA1c (p= 0.222 and 0.704,
respectively) as compared to other patients with T1DM.
There was no significant difference between children with
T1DM and pruritus and other children with T1DM as regards
age, sex, diabetes duration and HbA1c (p= 0.965, 0.822,
0.234, 0.621, respectively).Discussion
The prevalence of cutaneous manifestations in children and
adolescents with T1DM in the Diabetes Endocrine and
Figure 2 Prevalence of skin manifestations among males and females with type 1 diabetes. There was no significant sex difference in
patients with complications of insulin therapy and pruritus while, cutaneous bacterial and fungal infections were significantly higher in
females. Moreover, allergic diseases, pigmentary disorders were more common in males. Acne and Hyperhidrosis of hands were observed
only in male patients.
Table 2 The mean age, diabetes duration, and HbA1c in children with diabetes (group I) and different skin manifestations (n= 152).
Cutaneous manifestations Age (year)
(mean ± SD)
Diabetes duration (years)
(mean ± SD)
HbA1c (%)
(mean ± SD)
Complications of insulin Treatment (n= 44) 9.49 ± 3.38 3.62 ± 2.78 8.38 ± 2.25
Cutaneous infections (n= 38) 6.76 ± 3.71 3 ± 1.59 7.73 ± 1.41
Bacterial infections (n= 19) 6.42 ± 3.4 2.33 ± 2.17 7.69 ± 1.27
Fungal infections (n= 17) 6.88 ± 3.49 2.08 ± 1.91 8.02 ± 1.57
Viral infections (n= 2) 7 ± 4.24 2.5 ± 0.71 7.5 ± 1.41
Allergic diseases (n= 29) 7.62 ± 4.66 2.2 ± 2.99 7.82 ± 1.5
Pruritus (n= 23) 8.37 ± 2.87 2.72 ± 3.96 8.31 ± 2.17
Pigmentary disorders and nevi (n= 4) 11.25 ± 1.5 3.31 ± 2.09 8.27 ± 2.36
Hyperkeratosis of soles (n= 4) 8.5 ± 4.04 2.46 ± 2.26 8.75 ± 3.18
Hair disorders (n= 3) 12 ± 1.73 4.83 ± 3.17 6.36 ± 0.23
Parasitic infestations (n= 2) 8 ± 5.65 0.37 ± 0.17 6.45 ± 0.07
Acne (n= 1) 13 1 6
Keratosis pilaris (n= 1) 15 3 6.5
Rubeosis faciei (n= 1) 6.5 4 7.2
Hyperhidrosis of hands (n= 1) 14.5 1.5 8.5
Acanthosis nigricans (n= 1) 10 8 6.9
HbA1c: glycated hemoglobin, SD: standard deviation.
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agrees with Sawatkar et al. and Pavlovic´ et al., who found a
prevalence of 67.8%, 68%, respectively.4,3
This study demonstrated that complications of insulin
treatment were the most prevalent cutaneous manifestation
among children with T1DM, as they were observed in 28.9%
of the study group. This is in contrast to the finding of
Kordonouri et al. and Kordonouri et al., who reported a
prevalence of 48%. This can be explained by the different
mean duration and control of diabetes across the studies.5,6
In this work the patients suffering from cutaneous compli-
cations of insulin therapy were significantly older and showed
longer duration of diabetes when compared with others notpresenting with the same complications. This was in agreement
with Omar et al.7 Repeated trauma due to the repeated
injections in the same site may be behind the development of
lipohypertrophy, so to prevent such local skin reaction;
insulin-treated patients should be more intensively trained to
regularly change injection sites.8
There was no significant difference between the patients
with T1DM (group I) and the control group (group II) as
regards the bacterial and fungal infections (p= 0.737, 0.565,
respectively). This agrees with the finding of Pavlovic´, who
reported no significant difference between patients with
T1DM and the controls3 while, it is in contrast to Simone
et al., who reported increased susceptibility to infections in
48 R.M. Youssef et al.patients with diabetes.9 This may be due to the regular follow
up, the careful medical supervision and the early and prompt
treatment of any infection presenting among the children with
T1DM.
Viral infections were observed in 1.3% of children with
T1DM. Actually, only two diabetic patients presented with
warts. Close to our findings were Khurshid et al., who detected
viral infections in 2.9% of diabetic patients.10
Allergic skin diseases were the third common cutaneous
disorder encountered in children with T1DM in this study
(19.1%), they occurred in patients with shorter durations of
diabetes. The prevalence of eczema among the children with
T1DM in this study was 6.9%. This is in contrast to
Rosenbauer et al., who found that atopic eczema was signifi-
cantly associated with a reduced risk of type 1 diabetes.11
The classical explanation of that observation is based on the
type 1 and type 2 immune response mechanisms. Type 1
responses made up of Th1 cells and cytokine interferon gamma
have been implicated in the pathogenesis of autoimmune dis-
eases such as type I diabetes. Type 2 responses on the other
hand, are mediated via Th2 cells and interleukin 4, 5 and 13
and play a major role in the pathogenesis of allergic diseases
and eczema. The classical Th1/Th2 model proposes that Th1
inflammation suppresses the development of atopy whereas
Th2 inflammation suppresses the onset or severity of some
autoimmune diseases such as type 1 diabetes through a process
of counter-regulation. Thus, in accordance with the Th1/Th2
paradigm development of atopic eczema in early childhood
could be protective against childhood type 1 diabetes.12 In this
study the patients diagnosed with eczema reported that eczema
started after the onset of diabetes. It seems also reasonable to
ask whether the inverse relation between childhood eczema
and type 1 diabetes in individuals may be explained by genetic
factors. Both the HLA genes and polymorphisms in the
CTLA4 and PTPN22 genes are important in immune regula-
tion and are plausible candidate genes in atopic disorders as
well.13,14 On the other hand, Stene et al. demonstrated directly
that the established genetic susceptibility loci for type 1 dia-
betes (CTLA4 and PTPN22), though important in immune
regulation and may play a role also in atopic disorders, do
not explain the inverse association between childhood eczema
and the subsequent risk for type 1 diabetes previously
reported.15
Despite acanthosis nigricans being a sign of insulin resis-
tance and usually linked to type 2 diabetes, one female patient
with T1DM had acanthosis nigricans. This female patient had
familial acanthosis nigricans, she was not obese and had family
history of acanthosis nigricans.
In this study generalized pruritus was highly observed
among children with T1DM (15.1%) and was the fourth com-
mon cutaneous manifestation found. This makes it an impor-
tant cutaneous manifestation of T1DM. In accordance with
our results, were Najdawi and Faouri, Yamaoka et al., who
observed pruritus in 15.1% and 12%, respectively.16,17
Several cutaneous mediators have been suggested to cause
pruritus and could be linked to metabolic changes in diabetes.
Diffuse persistent pruritus without an identifiable clinical
cause (pruritus sine material) as well as forms of prurigo,
especially prurigo simplex subacuta are commonly observed
in patients with diabetes.18 Truncal pruritus can be induced
by two mechanisms. First, sympathetic dysfunction may
cause diminished sweat production and results in a dry skin.A second mechanism could be the damage to sensory c-fibers
by diabetic poly neuropathy.19
What was skeptical in our work was that non segmental
vitiligo was not diagnosed in children with T1DM, though
the association between diabetes and vitiligo is well known
as diabetes mellitus and vitiligo share a common risk factor
of familial predisposition. Diabetes is often present in close rel-
atives of patients with vitiligo and both diabetes and vitiligo
are associated with HLADR3 and HLADR4. Moreover both
diabetes and vitiligo share a common theory of autoimmu-
nity.20 This may be due to the relatively small number of
patients enrolled in our study.Conclusion
The prevalence of cutaneous manifestations in children and
adolescents with T1DM in the Diabetes Endocrine and Meta-
bolism Pediatric Unit (DEMPU) was 67.56%. Complications
of insulin treatment especially lipohypertrophy, were the most
prevalent cutaneous manifestation among children with
T1DM. Cutaneous infections among children with T1DM
came in the second order among the cutaneous disorders. Can-
didal infections especially monilial vulvovaginitis were the most
common fungal infection observed in children with T1DM.
Generalized pruritus is a common cutaneous symptom among
children with T1DM. Pigmentary disorders and hyperkeratosis
of the sole were more prevalent in children with T1DM.Conflict of interest
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